Blu Pharmaceuticals Opens Puerto Rico Plant
04/14/2010
"The stars aligned for us in Puerto Rico," said Bill Luster, president of Blu Pharmaceuticals. "We were able to acquire a state-of-the-art manufacturing facility for pennies on the dollar of what it would have cost for us to build an operation from the ground up, plus we were able to tap into a highly talented work force."
The Economic Development Bank for Puerto Rico and Small Business Administration extended $10 million in financing to purchase the facility and equipment. The Puerto Rico Industrial Development Company also offered economic incentives to attract Blu.
"In today's tough financing environment, it made a big difference that the Puerto Rican government was willing to partner with us to help finance the project," Luster said.
Blu Caribe will produce seven different drugs, including ciprofloxacin, an anthrax antidote. It also plans to open a research and development segment. Blu supplies generic drugs to wholesalers, group purchasing organizations, mail order pharmacies, and government agencies including the Veteran's Administration, Bureau of Prisons, Indian Health Services, and the Department of Defense.
Project Announcements
Swiss-Based Temenos Plans Orlando, Florida, Operations
06/23/2025
Phoenix Manufacturing Expands Glasgow, Missouri, Operations
06/23/2025
Otto Aviation Plans Jacksonville, Florida, Manufacturing Operations
06/20/2025
AMI Metals Expands Spokane, Washington, Production Operations
06/20/2025
Newly Weds Foods Plans Dyersburg, Tennessee, Production Operations
06/20/2025
Yaskawa American Expands Franklin, Wisconsin, Headquarters Operations
06/19/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
The New Math Behind Mexico and U.S. Manufacturing Decisions
Q2 2025